COVID-19 (SARS-CoV-2 infection) Infections and Infestations
Conditions
Interventions
This is a prospective paired sample study where whole blood from each chosen patient is used for harvesting COVID-19 convalescent plasma using both the Hemoclear filter device and the centrifugal meth
Sponsors
Academic Hospital Paramaribo
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Were sick with a coronavirus infection (but do not need to have been hospitalized). Free of symptoms for at least 2 weeks (no more coughing, no fever, no cold symptoms, taste and smell are back). The infection must be proven by a test from B.O.G. or the Academic Hospital. 2. Weigh at least 50 kg 3. At least 18 years old 4. Never received blood or plasma transfusions in the past 5. In good health 6. Not have or not previously had hepatitis B, C, HIV or syphilis. This will be tested for. If participants do not want to know, they cannot participate in this study
Exclusion criteria
Exclusion criteria: Have or have previously had hepatitis B, C, HIV or syphilis or do not want to be tested for this
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total antibody load per ml in convalescent plasma, measured using a validated spike protein ELISA assay at the timepoint of production of convalescent plasma by either the centrifugal or microfiltration method (t1) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Procedure time, including setup and priming of the hemoclear filter and centrifugation system, measured as the time between the start of set-up (t0) and finishing the convalescent plasma procedure (t1) 2. Blood cell losses measured using Hemaocrit in convalescent plasma at timepoint t1 compared with whole blood Hematocrit at the donation timepoint (td) 3. Levels of IgG, IgM , IgA and fibrinogen measured from whole blood after collection of donor blood (td). After processing and production of convalescent plasma, samples are drawn to perform the same measurements (t1) in order to calculate the efficacy of removal. 4. Virus neutralization determined by measuring plasma neutralizing antibodies (nAbs) in the samples after production of CP (t1). The total plasma levels of antibodies against spike region S1 are measured using an ELISA assay. The nAb titer will be calculated as the highest plasma dilution that eliminated the cytopathic effect in 50% of the wells (NT50). | — |
Countries
Suriname
Outcome results
None listed